This BSH guideline summarises the recommended initial investigation and first-line management of large B-cell lymphoma (LBCL). Primary extra-nodal LBCL is discussed in this guideline, with the exception of lymphoma involving the central nervous system, covered by separate BSH guideline publications.1, 2 Post-transplant lymphoproliferative disorders are also covered by a separate guideline.3 The investigation and management of primary mediastinal large B-cell lymphoma, mediastinal grey-zone lymphoma, primary cutaneous LBCL, primary effusion lymphoma, plasmablastic lymphoma and Burkitt lymphoma are also beyond the scope of this guideline. The management of relapsed LBCL is covered in a separate guideline.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.